⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 15, 2024Open Access

Supplementary Figure S3 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors

Timothy A. Yap Anthony W. Tolcher Ruth Plummer Jatinder Kaur Mukker Marta Enderlin Christine Hicking Thomas Grombacher Giuseppe Locatelli Zoltán Szűcs Ioannis Gounaris Johann S. de Bono

View Full Paper

Ask AI

Bookmark

Share

Abstract

Figure S3. CT scans showing partial response to tuvusertib treatment in one patient with platinum- and PARP inhibitor-resistant BRCAwt ovarian cancer, receiving a dose of tuvusertib 150 mg BID 4 days on/3 days off.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yap et al. (2024) studied this question.

synapsesocial.com/papers/68e6a14db6db643587624f9d https://doi.org/10.1158/1078-0432.25826654

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S3 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors2024
2Supplementary Figure S2 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors2024
3Supplementary Figure S2 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors2024
4Supplementary Figure S4 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors2024
5Supplementary Figure S4 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors2024